Related Experiment Videos
[PyNPase expression and cancer progression in the colorectum]
Nihon Geka Gakkai Zasshi
|September 22, 1998
Summary
PyNPase, an enzyme, is significantly higher in colorectal cancer stroma than in cancer cells. High cancer cell PyNPase levels in stage IIIb correlate with poorer patient prognosis, suggesting its potential as a prognostic biomarker.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Context:
- Colorectal cancer (CRC) presents a significant global health challenge.
- Understanding the tumor microenvironment, including cancer-stroma interactions, is crucial for developing effective therapies.
- PyNPase (purine nucleoside phosphorylase) role in CRC is not fully elucidated.
Purpose:
- To quantify and compare PyNPase expression in colorectal cancer cells and their surrounding stroma.
- To investigate the correlation between PyNPase levels, clinicopathological features, and patient prognosis.
- To identify the cellular source of PyNPase in the tumor microenvironment and its functional implications.
Summary:
- Western blotting analysis of 98 colorectal cancers revealed significantly higher PyNPase levels in the stroma fraction (SF) (70.2 units/mg) compared to the cancer fraction (CF) (45.1 units/mg) (p < 0.0001).
- PyNPase in SF correlated with vessel density, while high PyNPase in CF of stage IIIb patients indicated poorer prognosis (p < 0.05).
- Immunohistochemistry identified macrophages (M phi) as the primary source of SF PyNPase. In vitro, M phi stimulation enhanced PyNPase production and 5'-deoxyribouridine (5'DFUR) conversion to 5-fluorouracil (5-FU).
Impact:
- This study highlights PyNPase as a potential prognostic biomarker in colorectal cancer, particularly its expression within cancer cells.
- Identifies tumor-associated macrophages as key producers of PyNPase in the stroma.
- Suggests a potential role for PyNPase in modulating the tumor microenvironment and influencing therapeutic efficacy, possibly through 5-FU generation.